Technical analysis in the current KPTI stock forecast shows the 50-day moving average attempting to cross above the 200-day MA, a possible golden cross scenario if buying pressure continues. It is a pleasure to report that the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is up 139% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share price is down a whopping 90% in the last three years. Arguably, the recent bounce is to be expected after such a bad drop. Of course the real question is whether the business can sustain a turnaround. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. But, for KPTI, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Investors tracking the KPTI stock forecast are watching resistance near $2.